Literature DB >> 1728453

Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction.

J E Buring1, G T O'Connor, S Z Goldhaber, B Rosner, P N Herbert, C B Blum, J L Breslow, C H Hennekens.   

Abstract

BACKGROUND: A large and consistent body of evidence supports the judgment that elevation of total plasma blood cholesterol is a cause of myocardial infarction (MI) and that high levels of low density lipoprotein (LDL) cholesterol have a positive relation and high levels of high density lipoprotein (HDL) cholesterol an inverse relation with MI. At present, however, the roles, if any, of the major subfractions of HDL, namely, HDL2 and HDL3, have not been clarified. In addition, the relation of plasma apolipoprotein concentrations to MI and whether they provide predictive information over and above their lipoprotein cholesterol associations is unknown. METHODS AND
RESULTS: We evaluated these questions in a case-control study of patients hospitalized with a first MI and neighborhood controls of the same age and sex. Cases had significantly lower levels of total HDL (p less than 0.0001) as well as HDL2 (p less than 0.0001) and HDL3 (p less than 0.0001) cholesterol. These differences persisted after controlling for a large number of demographic, medical history, and behavioral risk factors and levels of other lipids. There were significant (p less than 0.0001) inverse dose-response relations with odds ratios for those in the highest quartile relative to those in the lowest of 0.15 for total HDL, 0.17 for HDL2, and 0.29 for HDL3 cholesterol levels. Levels of LDL and very low density lipoprotein cholesterol and triglycerides were also higher among cases than controls, but only for triglycerides was the difference statistically significant after adjustment for coronary risk factors and other lipids (p = 0.044). Apolipoproteins A-I and A-II were both significantly (p less than 0.0001) lower in cases, and differences remained even after adjustment for coronary risk factors and lipids. There were significant dose-response relations for both apolipoprotein A-I (p = 0.026) and A-II (p = 0.002). Neither apolipoprotein B nor E was significantly related to MI after adjustment for lipids and other coronary risk factors. When all four apolipoproteins were taken together, there was an increased level of prediction of MI over the information provided by the lipids and other coronary risk factors (p = 0.003), but this appeared present only for the individual apolipoproteins A-I (p = 0.027) and A-II (p = 0.011).
CONCLUSIONS: These data indicate that both HDL2 and HDL3 cholesterol levels are significantly associated with MI. They also raise the possibility that apolipoprotein levels, especially A-I and A-II, may add importantly relevant information to determination of risk of MI.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728453     DOI: 10.1161/01.cir.85.1.22

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  33 in total

1.  Lipid profile, haemostatic variables and angiographically-defined coronary artery disease: a cross-sectional study in an Irish population.

Authors:  J Galvin; M Codd; S Leavy; D Sugrue
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

Review 2.  Statin use in the metabolic syndrome.

Authors:  Justin B Lundbye; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

3.  Separation of the principal HDL subclasses by iodixanol ultracentrifugation.

Authors:  Nicola L Harman; Bruce A Griffin; Ian G Davies
Journal:  J Lipid Res       Date:  2013-05-20       Impact factor: 5.922

4.  Beyond the rodent model: Calorie restriction in rhesus monkeys.

Authors:  M A Lane; D K Ingram; G S Roth
Journal:  Age (Omaha)       Date:  1997-01

5.  Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness: The Northern Manhattan Study.

Authors:  Eduard Tiozzo; Hannah Gardener; Barry I Hudson; Chuanhui Dong; David Della-Morte; Milita Crisby; Ronald B Goldberg; Mitchell S V Elkind; Ying Kuen Cheung; Clinton B Wright; Ralph L Sacco; Moise Desvarieux; Tatjana Rundek
Journal:  Stroke       Date:  2016-05-10       Impact factor: 7.914

Review 6.  The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.

Authors:  L Tian; M Fu
Journal:  J Endocrinol Invest       Date:  2011-06       Impact factor: 4.256

7.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

8.  Effects of exercise with varying energy expenditure on high-density lipoprotein-cholesterol.

Authors:  P S Visich; F L Goss; P M Gordon; R J Robertson; V Warty; B G Denys; K F Metz
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

9.  Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis.

Authors:  Haitham M Ahmed; Michael Miller; Khurram Nasir; John W McEvoy; David Herrington; Roger S Blumenthal; Michael J Blaha
Journal:  Am J Epidemiol       Date:  2016-04-18       Impact factor: 4.897

10.  Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.

Authors:  Theodore W K Ng; Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-10-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.